The adrenaline receptor studied is a member of the G protein-coupled receptor (GPCR) family, and this family is the target of one-third of all Food and Drug Administration (FDA)-approved drugs.

The analyst says that SEPN’s advanced platform accelerates the discovery of novel GPCR-targeting therapeutics, addressing a significant unmet need. Leveraging CryoEM technology, SEPN ...